文献速递结核与非结核分枝杆菌

儿童潜伏性结核感染短程含利福霉素方案与9个月异烟肼方案的系统综述与荟萃分析

Shorter Antitubercular Regimens Versus 9 Months of Isoniazid for Latent Tuberculosis in Children: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该系统综述与荟萃分析比较儿童潜伏性结核感染使用9个月异烟肼(9H)与短程含利福霉素方案的有效性与安全性,纳入5项随机对照试验和7项非随机研究。观察性数据与之一致,支持当前指南偏好短程方案。

要点

  • 不良事件两组相似,但证据确定性低。

核心结论

  • 儿童潜伏性结核感染使用短程含利福霉素方案可能提高治疗完成率,安全性相似,结核病发病与9H无重要差异。

研究设计与样本

  • 系统检索MEDLINE、Embase和Cochrane对照试验中心注册库至2025年6月,纳入比较儿童(1-18岁)短于9个月异烟肼方案的随机对照试验和队列研究。

主要发现

  • 不良事件两组相似,但证据确定性低。
  • 观察性数据与随机对照试验结果一致,显示短程治疗完成率更高且肝毒性更低。

关键数值与推荐

  • 不良事件比较:证据确定性低。

临床怎么用

  • 研究结果支持当前指南推荐,在儿童潜伏性结核感染中优先选择短程含利福霉素方案。
  • 短程方案可能提高治疗完成率且不增加结核病发病风险,但需结合个体情况评估安全性。

局限性

  • 不良事件证据确定性低,安全性结论尚不确定。
  • 纳入研究包含非随机设计,可能存在偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a systematic review and meta-analysis to compare effectiveness and safety of 9 months of isoniazid (9H) versus shorter rifamycin-containing regimens for treating latent tuberculosis infection (TBI) in children. METHODS: We systematically searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials to June 2025 for randomized, controlled trials (RCTs) and cohort studies that compared regimens that were shorter than 9 months of isoniazid in children aged 1-18 years. Outcomes were development of TB disease, treatment completion, and adverse events. Risk of bias was assessed using RoB 2.0 and the Risk Of Bias In Non-Randomized Studies - of Interventions (ROBINS-I) tool; certainty of evidence was graded using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). RESULTS: Five RCTs and 7 nonrandomized studies that enrolled approximately 2950 children in trials and >25 000 in observational cohorts were included. In pooled analysis of 3 RCTs, shorter rifamycin-containing regimens resulted in little to no difference in development of TB disease compared with 9H (odds ratio [OR], 0.19; 95% confidence interval [CI], .03-1.12; moderate-certainty evidence). Treatment completion was probably higher with shorter regimens (OR, 0.51; 95% CI, .42-0.62; moderate-certainty evidence). Adverse events were similar between groups, but evidence is uncertain (low-certainty evidence). Observational data were consistent with these findings, showing higher completion rates and lower hepatotoxicity with shorter treatments. CONCLUSIONS: Shorter rifamycin-containing regimens for pediatric TBI probably increase treatment completion and have similar safety outcomes, with no important difference in development of TB disease compared with the standard regimen. These findings support current guideline recommendations that favor shorter regimens in children.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kosenko M, Davtian L, Iakovleva E, et al. Shorter Antitubercular Regimens Versus 9 Months of Isoniazid for Latent Tuberculosis in Children: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2026. PMID: 41805722. doi:10.1093/cid/ciag073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。